The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

4 months ago

Version History

1 additional source confirmed this story

Version 34 months ago

What changed: The story was updated to include Q1 earnings expectations for Mirum Pharmaceuticals and the significant sales growth of its drug Livmarli.

Version 24 months ago

What changed: Updated the story to include UBS raising Merck's price target and the company's announcement of a cash tender offer for Terns Pharmaceuticals.

Version 14 months ago

What changed: The story was updated to include details on Pfizer's competitive oncology strategy and its targeted therapeutic modalities.

StocksUpdated×3•Originally published 16 April 2026•Updated 18 April 2026•

1 min read

Merck Q1 Earnings Outlook Bolstered by Keytruda Sales Growth

Key Facts

1Keytruda accounts for more than half of Merck's pharmaceutical sales.

2Q1 sales growth is expected to be driven by new indications and strong market uptake.

Investors are closely monitoring Merck & Co.'s upcoming Q1 earnings as UBS raised its price target to $145, citing strong Keytruda performance and strategic M&A activity. Joining the sector spotlight, Mirum Pharmaceuticals (MIRM) enters the Q1 earnings season with a focus on its drug Livmarli, which delivered a remarkable 69% year-over-year growth in 2025. Revenue momentum for Mirum is further supported by its broadening portfolio of bile acid products. Meanwhile, Pfizer continues to intensify its oncology strategy through ADCs and immuno-oncology biologics to maintain its competitive edge. These developments underscore a period of intense innovation and portfolio expansion across the pharmaceutical landscape. Ultimately, the sustainability of sales growth and successful pipeline integration will be critical for these firms in the current fiscal year.

Sources:

zacks.com